Clinical Trials Logo

Ischemia clinical trials

View clinical trials related to Ischemia.

Filter by:

NCT ID: NCT03405506 Not yet recruiting - Clinical trials for Coronary Artery Disease

Functional Diagnostic Accuracy of Quantitative Flow Ratio in Tandem Lesions and Virtual Stenting

FORTRESS
Start date: February 2, 2018
Phase: N/A
Study type: Observational [Patient Registry]

Quantitative Flow Ratio (QFR) is a novel method for evaluating the functional significance of coronary stenosis. Virtual stent implantation technique combined with QFR was recently developed to predict the functional significance of coronary stenosis as if the stenosis was revascularized. The purpose of this study is to evaluate the diagnostic accuracy of QFR in in tandem lesions with fractional flow reserve (FFR) as the reference standard. The secondary purpose is to evaluate the diagnostic accuracy of QFR-based virtual stent technique in predicting the FFR values after revascularizing the culprit lesion.

NCT ID: NCT03295539 Not yet recruiting - Lower Limb Ischemia Clinical Trials

Acute Limb Ischaemia (ALI) Management With 'Indigo' Mechanical Aspiration System

Start date: November 1, 2017
Phase: N/A
Study type: Interventional

International Multi-Centre registry recording comprehensive data on the use of 'Indigo' Mechanical thrombectomy system by Penumbra Inc for the removal of acute clot causing acute or critical limb ischaemia.

NCT ID: NCT03219645 Not yet recruiting - Ischemic Stroke Clinical Trials

Ginkgo Diterpene Lactone Meglumine Injection on Platelet Reactivity in Acute Ischemic Stroke

GDPRS
Start date: July 15, 2017
Phase: Phase 2/Phase 3
Study type: Interventional

This study evaluates the addition of Ginkgo Diterpene Lactone Meglumine Injection to aspirin in the treatment of acute ischemic stroke.Half of patient will receive Ginkgo Diterpene Lactone Meglumine Injection(25mg once/day D1-D14) and aspirin(300mg loading dose,then 100mg once/day D2-D14) in combination, while the other half will receive aspirin(300mg loading dose,then 100mg once/day D2-D14).

NCT ID: NCT03163589 Not yet recruiting - Clinical trials for Hypoxic-Ischemic Encephalopathy

Erythropoietin in Management of Neonatal Hypoxic Ischemic Encephalopathy

Start date: December 1, 2017
Phase: Phase 3
Study type: Interventional

Perinatal hypoxic-ischaemic encephalopathy occurs in one to three infants per 1000 term births, and up to 12 000 infants are affected each year in the united state of America. Hypoxic ischemic encephalopathy is not preventable in most cases, and therapies are limited. Hypothermia improves outcomes and is the current standard of care. Yet clinical trials suggest that 44% to 53% of infants who receive hypothermia will die or suffer moderate to severe neurological disability. Therefore, novel neuroprotective therapies are urgently needed to further reduce the rate and severity of neurodevelopmental disabilities resulting from hypoxic ischemic encephalopathy. Erythropoietin is a novel neuroprotective agent, with remarkable neuroprotective and neuroregenerative effects in animals. Rodent and primate models of neonatal brain injury support the safety and efficacy of multiple erythropoietin doses for improving histological and functional outcomes after hypoxia-ischaemia.

NCT ID: NCT03153878 Not yet recruiting - Clinical trials for Ischemic Heart Disease

The Prospective Cohort Study on the Benefit-risk of Antithrombotic or Anticoagulant Therapy in Patients With Unruptured Intracranial Aneurysms Associated With Ischemic Heart Disease or Ischemic Cerebrovascular Disease

Start date: June 1, 2017
Phase: N/A
Study type: Observational [Patient Registry]

This is a registry study of the natural course of unruptured intracranial aneurysms (UIA). In addition, the investigators will analyze the benefit-risk of antithrombotic or anticoagulant therapy in patients with unruptured intracranial aneurysms associated with ischemic heart disease or ischemic cerebrovascular disease. The investigators aim to use research data to create a China national database of UIA

NCT ID: NCT03152799 Not yet recruiting - Ischemic Stroke Clinical Trials

Remote Ischaemic Conditioning in Endovascular Recanalization for Proximal Anterior Circulation Occlusion Study

RICE PAC
Start date: August 1, 2017
Phase: Phase 1
Study type: Interventional

Ischaemic stroke causes significant morbidity and mortality and is a leading cause of disability within an ageing United Kingdom (UK) population. Proximal anterior circulation occlusion is associated with a particularly poor prognosis, but its management has undergone a paradigm shift following clinical introduction of endovascular recanalization, establishing rapid reperfusion of the ischaemic penumbra. Remote ischaemic conditioning (RIC) is highly effective at attenuating cerebral infarction in basic research studies and has the potential to further improve patient outcome if used as an adjunct to invasive revascularisation strategies. We aim to trial remote ischaemic conditioning at the time of revascularisation, and then daily for the duration of the seven-day in-patient stay, compared to a sham conditioning procedure. This pilot, single-centre study will determine efficacy/ tolerability of RIC to reduce cerebral infarction (primary endpoint: determined by brain magnetic resonance imaging [MRI]) and improve functional status (secondary end-points: National Institutes of Health Stroke Severity (NIHSS); European Quality of Life questionnaire EurQoL), with the data providing the necessary parameters for power calculations and leveraging charitable funding for a subsequent multi-centre study.

NCT ID: NCT03116438 Not yet recruiting - Clinical trials for Coronary Artery Disease

CADence Performance as a Rule-Out Modality in Long Beach Veterans Administration Heart Catheterization Lab Patients

SOLDIER
Start date: June 16, 2017
Phase: N/A
Study type: Interventional

The purpose of the study is to evaluate the safety and performance of the CADence device by comparing it to the results obtained from standard coronary angiography. The CADence device collects acoustic (sound) data from locations on the chest for the purpose of identifying coronary artery turbulence, which may be indicative of coronary artery disease.

NCT ID: NCT03098771 Not yet recruiting - Clinical trials for Atherosclerotic Ischemic Disease

Peripheral Blood Autologous CD34+ Cell Transplantation Promotes Angiogenesis With Atherosclerotic Ischemia for Elderly

Start date: January 2018
Phase: N/A
Study type: Interventional

To verify angiogenesis in elderly patients with atherosclerotic ischemia after peripheral blood autologous CD34+ cell transplantation.

NCT ID: NCT03079674 Not yet recruiting - Clinical trials for Transient Ischemic Attack

China Registry of Non-disabling Ischemic Cerebrovascular Events

CR-NICE
Start date: June 1, 2017
Phase: N/A
Study type: Observational [Patient Registry]

The burden of non-disabling ischemic cerebrovascular events (NICE) is significantly increased. In order to achieve accurate risk stratification and effective treatments, developing new diagnostic, therapeutic, and prognostic strategies is indispensable. Chinese registry of NICE is a national multi-center prospective study aimed to explore the epidemiology, new biomarkers, risk factors and prognostic models.

NCT ID: NCT03079492 Not yet recruiting - Clinical trials for Hypoxic-Ischemic Encephalopathy

MRI of Neonate With HIE Before and During the Moderate Hypothermia

Start date: June 1, 2017
Phase: N/A
Study type: Observational [Patient Registry]

Moderate hypothermia has been demonstrated to be the effective treatment for neonates with hypoxic-ischemic encephalopathy (HIE). However, few studies reveal the actual alterations in physiological parameters (i.e. brain temperature and cerebral blood flow) of neonates undergoing cooling, especially for HIE lesions. Therefore, this project aims to utilize the magnetic resonance imaging (MRI), i.e. MR thermal imaging and phase contrast MRI to measure the changes of these parameters before and during hypothermia; and then make comparisons with the routine nasopharyngeal and rectal temperature. All these would provide in vivo quantitative data for therapeutic evaluation and promote the optimization.